<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/35/156" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/35/156/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/35/156/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_156"><akn:num>156</akn:num><akn:heading>Extension of patent term</akn:heading><akn:content><akn:p>§ 156. Extension of patent term(a) The term of a patent which claims a product, a method of using a product, or a method of manufacturing a product shall be extended in accordance with this section from the original expiration date of the patent, which shall include any patent term adjustment granted under section 154(b), if—(1) the term of the patent has not expired before an application is submitted under subsection (d)(1) for its extension;

(2) the term of the patent has never been extended under subsection (e)(1) of this section;

(3) an application for extension is submitted by the owner of record of the patent or its agent and in accordance with the requirements of paragraphs (1) through (4) of subsection (d);

(4) the product has been subject to a regulatory review period before its commercial marketing or use;

(5)(A) except as provided in subparagraph (B) or (C), the permission for the commercial marketing or use of the product after such regulatory review period is the first permitted commercial marketing or use of the product under the provision of law under which such regulatory review period occurred;

(B) in the case of a patent which claims a method of manufacturing the product which primarily uses recombinant DNA technology in the manufacture of the product, the permission for the commercial marketing or use of the product after such regulatory review period is the first permitted commercial marketing or use of a product manufactured under the process claimed in the patent; or

(C) for purposes of subparagraph (A), in the case of a patent which—(i) claims a new animal drug or a veterinary biological product which (I) is not covered by the claims in any other patent which has been extended, and (II) has received permission for the commercial marketing or use in non-food-producing animals and in food-producing animals, and

(ii) was not extended on the basis of the regulatory review period for use in non-food-producing animals,


the permission for th</akn:p></akn:content><akn:subsection eId="subsec_156_a"><akn:num>(a)</akn:num><akn:content><akn:p>(a) The term of a patent which claims a product, a method of using a product, or a method of manufacturing a product shall be extended in accordance with this section from the original expiration date of the patent, which shall include any patent term adjustment granted under section 154(b), if— The product referred to in paragraphs (4) and (5) is hereinafter in this section referred to as the “approved product”.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_156_b"><akn:num>(b)</akn:num><akn:content><akn:p>(b) Except as provided in subsection (d)(5)(F), the rights derived from any patent the term of which is extended under this section shall during the period during which the term of the patent is extended— As used in this subsection, the term “product” includes an approved product.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_156_c"><akn:num>(c)</akn:num><akn:content><akn:p>(c) The term of a patent eligible for extension under subsection (a) shall be extended by the time equal to the regulatory review period for the approved product which period occurs after the date the patent is issued, except that—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_156_d"><akn:num>(d)</akn:num><akn:content><akn:p>(d)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_156_e"><akn:num>(e)</akn:num><akn:content><akn:p>(e)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_156_f"><akn:num>(f)</akn:num><akn:content><akn:p>(f) For purposes of this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_156_g"><akn:num>(g)</akn:num><akn:content><akn:p>(g) For purposes of this section, the term “regulatory review period” has the following meanings:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_156_h"><akn:num>(h)</akn:num><akn:content><akn:p>(h) The Director may establish such fees as the Director determines appropriate to cover the costs to the Office of receiving and acting upon applications under this section.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_156_i"><akn:num>(i)</akn:num><akn:content><akn:p>(i)</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>